NCT03726931View on ClinicalTrials.gov

FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

January 29, 2023

Study Completion Date

January 29, 2023

Conditions
Breast Cancer
Interventions
DIAGNOSTIC_TEST

18F-Fluorestradiol PET/CT scan

\[18F\]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.

Trial Locations (1)

Unknown

VU University Medical Center, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER

NCT03726931 - FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET | Biotech Hunter | Biotech Hunter